Australia's most trusted
source of pharma news
Posted 29 October 2024 PM
The United States National Institutes of Health (NIH) has granted Aussie biotech Vaxxas the licence to a vaccine antigen candidate (DS2), to protect against Respiratory Syncytial Virus (RSV).
Vaxxas' worldwide licence from the NIH enables the company to develop the first needle-free, room-temperature stable RSV vaccine to enter clinical studies.
The DS2 RSV vaccine antigen candidate was developed by scientists at the NIH's Vaccine Research Centre and the National Institute of Allergy and Infectious Diseases.
"Published preclinical results show the potential immunogenic advantages of this antigen candidate as the basis for an RSV vaccine to provide robust and durable protection," Vaxxas CEO David Hoey said.
"These potential advantages, coupled with the potential of the Vaxxas needle-free technology to eliminate the need for refrigerated distribution and enable self-administration, could offer a vaccine that makes a significant impact on the way we protect populations against this serious respiratory infection in the future."
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.